TITLE

SHIRE GETS FDA APPROVABLE LETTER FOR DAYTRANA FOR ADHD

PUB. DATE
February 2006
SOURCE
Worldwide Biotech;Feb2006, Vol. 18 Issue 2, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the approval given by the U.S. Food and Drug Administration to DAYTRANA, an investigational methylphenidate transdermal system developed by Shire PLC. Use of the drug for treating attention deficit hyperactivity disorder (ADHD) in children; Remarks from company CEO Matthew Emmens regarding the drug approval; Clinical information on ADHD.
ACCESSION #
20451863

 

Related Articles

  • SHIRE GETS FDA APPROVABLE LETTER FOR DAYTRANA FOR ADHD.  // Worldwide Videotex Update;Feb2006, Vol. 25 Issue 2, p119 

    The article reports on an approvable letter received by Shire plc from the U.S. Food and Drug Administration for its DAYTRANA or methylphenidate transdermal system for children with attention deficit hyperactivity disorder. The approvable letter includes proposed labeling, requests for data...

  • Shire/Noven: MTS back on track.  // PharmaWatch: Monthly Review;Sep2005, Vol. 4 Issue 9, p18 

    Reports on the submission of an application for a drug to treat pediatric attention-deficit hyperactivity disorder to the U.S. Food and Drug Administration by Shire Pharmaceuticals Group PLC and Noven Pharmaceuticals Inc. Information on a transdermal delivery system for methylphenidate; Benefits...

  • Opinion: Shire: Intuniv approval diversifies ADHD portfolio.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p14 

    The author focuses on the announcement of Shire Pharmaceuticals Group PLC on the approval by the Food & Drug Administration (FDA) of the Intuniv extended release tablets for the treatment of attention-deficit hyperactivity disorder (ADHD). It notes that Intuniv represents Shire's first venture...

  • Noven/Shire: a patch in the balance.  // PharmaWatch: Monthly Review;Jan2006, Vol. 5 Issue 1, p21 

    The article reports that the scientists of the U.S. Food and Drug Administration (FDA) have cast doubt on the eligibility of Noven Pharmaceutical Inc. and Shire Pharmaceutical Group PLC's Daytrana for getting approved. The briefing documents posted at the web site of the FDA advise that Daytrana...

  • Shire: Vyvanse grows up.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p14 

    The article reports on the approval set by the U.S. Food and Drug Administration (FDA) for Vyvanse by Shire Pharmaceuticals Group PLC as treatment for adult attention-deficit hyperactivity disorder (ADHD). FDA recommended the drug as the only once-daily prodrug stimulant available to treat...

  • Trandermal ADHD drug gets FDA nod.  // Drug Topics;5/8/2006, Vol. 150 Issue 9, p6 

    The article reports on the approval given by the U.S. food and Drug Administration to Daytrana, a new form of delivery for methylphenidate, for the treatment of attention deficit hyperactivity disorder. The drug from Shire Pharmaceuticals Group PLC, is a transdermal system that will deliver a...

  • ADHD therapy to be applied transdermally. Belden, Heidi // Drug Topics;5/22/2006, Vol. 150 Issue 10, p14 

    The article reports on the redevelopment of the Daytrana drug from Shire PLC as a treatment for children diagnosed with attention deficit or hyperactivity disorder (ADHD) in the U.S. Daytrana is a non-oral drug which was approved by the Food and Drug Administration to manage hyperactivity in...

  • ADHD Update.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p12 

    The article offers updates related to the treatment of attention-deficit hyperactivity disorder (ADHD) in the U.S. The Food and Drug Administration (FDA) has told manufacturers of ADHD drugs to develop medication guides. Shire and its partner New River Pharmaceuticals reported that the FDA has...

  • FDA: A NEW STRIPE OF ADHD TREATMENT FOR CHILDREN.  // Contemporary Pediatrics;Oct2009, Vol. 26 Issue 10, p18 

    The article reports that the U.S. Food and Drug Administration (FDA) has given approval to Shire for its new drug, guanfacine, which is an alpha-2A adrenergic receptor agonist. The drug can be administered to treat children as young as 6 years suffering from attention-deficit hyperactivity...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics